Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / A•• I•••••••

R••••••••• C•••••• P••••••• Makes Significant Investment in A•• I•••••••

Majority recapitalizationclosedannounced Apr 15, 2025closed Apr 15, 2025Fact
What happened
Target
A•• I•••••••
Platform
not an add-on on record
Control
Control
Share acquired
unknown
Industry
healthcare / infusion
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
10 named
Buy side
  • A•••••• H••••Deal partnerconfirmed
    ““R••••••••• strives to partner with strong management teams to build industry-leading companies,” said A•••••• H••••, Partner at R•••••••••.”
  • E••• H•••Deal partnerconfirmed
    ““Specialty infusion represents a high-priority investment focus area for R•••••••••, given the opportunity presented by the ongoing site of care shift and growing infusible drug pipeline,” said E••• H•••, Vice President at R•••••••••.”
  • R••••••••• C•••••• P••••••• F••• I••• L•••Fundconfirmed
    “AOM, a specialty infusion provider focused on chronic therapy management, is the ninth investment from R••••••••• C•••••• P••••••• Fund III.”
  • R••••••••• C•••••• P•••••••Sponsorconfirmed
    “R••••••••• C•••••• P••••••• (“R•••••••••”), a growth-oriented healthcare-focused private equity firm, announced today it completed a recapitalization of A•• I••••••• (“AOM” or the “Company”).”
Advisory side
  • H••••••• L••••Buy-side adviserconfirmed
    “Guggenheim Securities, LLC and H••••••• L•••• served as financial advisors and M••••••••• L•• served as legal counsel to R•••••••••.”
  • M••••••••• L••Legal adviserconfirmed
    “Guggenheim Securities, LLC and H••••••• L•••• served as financial advisors and M••••••••• L•• served as legal counsel to R•••••••••.”
  • M••••• • C•••••• L••Sell-side adviserconfirmed
    “J•••••••• L•• and M••••• & Company served as financial advisors to AOM.”
  • J•••••••• L••Sell-side adviserconfirmed
    “J•••••••• L•• and M••••• & Company served as financial advisors to AOM.”
Side not stated
  • K•••• M••••Managementconfirmed
    ““AOM is committed to growth that enhances patient care,” said K•••• M••••, CEO of AOM.”
  • A•• I•••••••Targetconfirmed
    “R••••••••• C•••••• P••••••• (“R•••••••••”), a growth-oriented healthcare-focused private equity firm, announced today it completed a recapitalization of A•• I••••••• (“AOM” or the “Company”).”
Evidence
“R••••••••• C•••••• P••••••• (“R•••••••••”), a growth-oriented healthcare-focused private equity firm, announced today it completed a recapitalization of A•• I••••••• (“AOM” or the “Company”).”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 15, 2026
R••••••••• C•••••• P••••••• Makes Significant Investment in A•• I••••••• | Private Equity Intelligence | DFX